Gilead Sciences PT Raised to $102.00 (GILD)
Stock analysts at UBS AG hoisted their target price on shares of Gilead Sciences (NASDAQ:GILD) from $80.00 to $102.00 in a report issued on Monday, AnalystRatings.NET reports. The firm currently has a “buy” rating on the stock. UBS AG’s price objective would suggest a potential upside of 37.24% from the stock’s previous close.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.70% during mid-day trading on Monday, hitting $73.06. The stock had a trading volume of 4,099,283 shares. Gilead Sciences has a 52-week low of $38.10 and a 52-week high of $76.11. The stock’s 50-day moving average is $73.12 and its 200-day moving average is $63.91. The company has a market cap of $112.0 billion and a price-to-earnings ratio of 40.90.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, October 29th. The company reported $0.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.
A number of other firms have also recently commented on GILD. Analysts at Citigroup Inc. raised their price target on shares of Gilead Sciences to $96.00 in a research note to investors on Monday. Separately, analysts at Maxim Group raised their price target on shares of Gilead Sciences from $89.00 to $98.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, December 31st. They now have a $89.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $80.04.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.